Details:
Under the partnership, EdiGene will work with the David Gamm Laboratory to evaluate the pharmacological property of LEAPER™ RNA employs short engineered ADAR-recruiting RNAs (arRNAs) base editing candidates targeting specific genetic diseases.
Lead Product(s): Short Engineered ADAR-recruiting RNAs
Therapeutic Area: Genetic Disease Product Name: arRNAs
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: University of Wisconsin–Madison
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2021